Filter by: Subject

Filter by: Subject

Results Per Page:

Prostate-specific membrane antigen (PSMA) (13)
Prostate cancer (7)
Positron emission tomography (PET) (4)
SDG-03: Good health and well-being (3)
68Ga-PSMA (2)
Actinium-225 (2)
Breast cancer (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
Positron emission tomography/computed tomography (PET/CT) (2)
Prostate carcinoma (2)
Prostate-specific antigen (PSA) (2)
Radioligand therapy (2)
Theranostics (2)
225Ac-PSMA-617 (1)
68Ga-DKFZ-PSMA-11 (1)
68Ga-HBED-CC-(Ahx)Lys-NH-CO-NH-Glu (1)
68Ga-PSMAHBED (1)
68Ga‐PSMA‐617 (1)
Angiogenesis (1)
Biochemical recurrence (1)
Biodistribution (1)
Bismuth-213 (1)
Black South-African (BSAs) (1)
Chemokine receptor 4 (CXCR-4) (1)
Chemotherapy-naïve (1)
Choline (1)
Docetaxel (1)
Fibroblast activating protein inhibitor (FAPI) (1)
Fibroblast activation protein inhibitors (FAPI) (1)
Flourodeoxyglucose (FDG) (1)
Gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) (1)
Gastrin-releasing peptide receptor (GRPR) (1)
Hepatocellular cancer (1)
Hepatocellular carcinoma (HCC) (1)
Human epidermal growth factor receptor 2 (HER2) (1)
Immunohistochemistry (IHC) (1)
In vitro (1)
Lutetium-177 (177Lu) (1)
Metastatic castrate-resistant prostate cancer (mCRPC) (1)
Metastatic prostate carcinoma (1)
Microemulsion (1)
Non-prostate carcinoma (1)
Overall survival (OS) (1)
PET/CT (1)
Positron emission tomography/computed tomography (PET/CT) (1)
Primary prostate carcinoma (PPC) (1)
Progression-free survival (PFS) (1)
PSA response (1)
PSMA-based alpha therapy (PAT) (1)
PSMA-GCK01 (1)
Racial differences (1)
Radical prostatectomy (1)
Radioligand therapy (RLT) (1)
Radiosensitizer (1)
Radiotherapy (1)
Re-challenge (1)
RLT/Radioligand therapy (1)
Single-photon emission computed tomography (SPECT) (1)
Targeted alpha therapy (1)
Targeted radionuclide therapy (1)
Technetium-99 m (1)
Tumour microenvironment (TME) (1)
White South-African (WSAs) (1)
Yttrium-90 (1)